The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry

Volume 85 • 2024 • Number 1

Back to top Open menu arrow
Archive Volume 85 Current Issue

Editorial

JCP
Truth: Keeping Us on Track in Scientific Publishing
Editorial

February 5, 2024

Editor-in-Chief Marlene P. Freeman, MD, reflects on the importance of peer-reviewed research in today’s world and recognizes the contributions of JCP authors and peer reviewers over the past year.
Marlene P. Freeman, MD

Systematic Review

JCP
Predictors and Risk Factors of Treatment-Resistant Depression: A Systematic Review
Systematic Review

November 13, 2023

Early identification of individuals with major depressive disorder who are likely to develop treatment-resistant depression (TRD) is needed. This study reviewed the literature to identify and categorize the predictors...
Shane J. O’Connor, MSc; Nilay Hewitt, PhD; Joanna Kuc, MSc; Lucinda S. Orsini, DPM, MPH
JCP
A Systematic Review of the Clinical Effects of Cannabis and Cannabinoids in Posttraumatic Stress Disorder Symptoms and Symptom Clusters
Systematic Review

February 14, 2024

This review of 14 studies did not find major benefits of cannabinoids in improving overall PTSD symptoms, although some benefits in cluster B and E symptoms were seen. Risks...
Justyne D. Rodas, MSc; Tony P. George, MD; Ahmed N. Hassan, MD

Original Research

JCP
A Comparison of Depressive Symptom Self-Reported Measures in the Texas Youth Depression and Suicide Research Network (TX-YDSRN)
Original Research

December 18, 2023

Three patient-reported outcomes—Patient Health Questionnaire for Adolescents, Quick Inventory of Depressive Symptomatology–Self-Report, and Very Quick Inventory of Depressive Symptomatology–Self-Report—can assess depressive symptom severity and change over time. Scores on...
Karabi Nandy, PhD; A. John Rush, MD; Thomas Carmody, PhD; Beth D. Kennard, PsyD; Graham J. Emslie, MD; Holli Slater, PhD; Taryn L. Mayes, MS; Melissa DeFilippis, MD; Cynthia Garza, PsyD; Eric A. Storch, PhD; Sarah M. Wakefield, MD; Madhukar H. Trivedi, MD
JCP
Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study
Original Research

January 15, 2024

At 4 weeks of treatment, patients receiving iloperidone showed significant improvement on the Young Mania Rating Scale versus those receiving placebo.
Rosarelis Torres, PhD; Emily L. Czeisler; Sean R. Chadwick, PhD; Stephen M. Stahl, MD, PhD; Sandra P. Smieszek, PhD; Changfu Xiao, PhD; Christos M. Polymeropoulos, MD; Gunther Birznieks, MS; Mihael H. Polymeropoulos, MD
JCP
Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series
Original Research

November 27, 2023

Six patients who screened positive for alcohol use disorder (AUD) received semaglutide for weight loss. All subsequently showed significant improvement in AUD symptoms.
Jesse R. Richards, DO; Madisen Fae Dorand, MD; Kyleigh Royal; Lana Mnajjed; Maria Paszkowiak; W. Kyle Simmons, PhD
JCP
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study
Original Research

December 27, 2023

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.
Andrew J. Cutler, MD; Gregory W. Mattingly, MD; Susan G. Kornstein, MD; Scott T. Aaronson, MD; Robert Lasser, MD; Hongling Zhang, MSc; Nilanjana Rana, MBBS; Colville Brown, MD; Seth Levin, MD; Catherine Miller, PharmD; Mona Kotecha, MD; Fiona Forrestal, MSc; James Doherty, PhD
JCP
Telemental Health Utilization in Commercial Health Insurance Plans in the United States From 2010 Through 2019
Original Research

November 20, 2023

The proportion of mental health visits delivered via telemental health increased from 0.002% to 0.162% between 2010¬–2019. Patients aged 18–34 and those in the western US had the highest...
Aziza Arifkhanova, PhD; Andrew Elhabr, PhD; Christian Murray, MS; Jaya Khushalani, PhD; Antonio Neri, MD; Jennifer Kaminski, PhD; Richard W. Puddy, PhD; Turgay Ayer, PhD
JCP
Acceptance and Mindfulness-Based Exposure Therapy for PTSD After Cardiac Arrest: An Open Feasibility Trial
Original Research

November 22, 2023

Eighty percent of patients had significant response to therapy, with 70% showing diagnostic remission of PTSD after 8 sessions.
Maja Bergman, PhD; John C. Markowitz, MD; Ian M. Kronish, MD, MPH; Sachin Agarwal, MD, MPH; Chana T. Fisch, BA; Elizabeth Eder-Moreau, MA; Yuval Neria, PhD
JCP
Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report
Original Research

November 15, 2023

Quality of life is an important patient-centric outcome. Using machine learning methods, this study found that quality of life improvement with antidepressant treatment can be predicted using early depression...
Tejas Phaterpekar, MDS; John-Jose Nunez, MD, MSc; Emma Morton, PhD; Yang S. Liu, PhD; Bo Cao, PhD; Benicio N. Frey, MD, PhD; Roumen V. Milev, MD, PhD; Daniel J. Müller, MD, PhD; Susan Rotzinger, PhD; Claudio N. Soares, MD, PhD; Valerie H. Taylor, MD, PhD; Rudolf Uher, MD, PhD; Sidney H. Kennedy, MD; Raymond W. Lam, MD
JCP
Social Media Images Can Predict Suicide Risk Using Interpretable Large Language-Vision Models
Original Research

November 29, 2023

Recent studies predicting signs of suicide risk from social media using artificial intelligence have been limited by methodological and conceptual factors. This study presents an interpretable prediction model of...
Yael Badian, MSc; Yaakov Ophir, PhD; Refael Tikochinski, MA; Nitay Calderon, MSc; Anat Brunstein Klomek, PhD; Eyal Fruchter, MD; Roi Reichart, PhD
JCP
CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders
Original Research

January 17, 2024

Genetic testing of CYP2D6 did not show that predicted poor drug metabolism led to increased adverse drug reactions in patients with depression.
Amanda Holck, MD; Marie Asp, MD, PhD; Henrik Green, PhD; Åsa Westrin, MD, PhD; Margareta Reis, PhD
JCP
Factors Associated With Oral Anticoagulant Use in Patients With Atrial Fibrillation and Mental Disorders
Original Research

January 3, 2024

People with atrial fibrillation (AF) and comorbid mental illness are less often prescribed an oral anticoagulant (OAC) for AF-related stroke prevention. This study examined how mental illness interacts with...
Dina Farran, MSc, MPH; Matthew Broadbent, MA (hons); Aikaterini Dima, MD, MSc; Mark Ashworth, DM; Fiona Gaughran, MD
JCP
Magnitude and Correlates of Symptomatic, Global Illness, and Social Functioning Response; Out-of-Home Placement; and Length of Stay in 1,189 Consecutively Hospitalized Children and Adolescents With Mental Disorders
Original Research

December 27, 2023

This retrospective analysis of clinical parameters in youth hospitalized for psychiatric treatment assessed magnitude and correlates of symptom response, global illness response, social functioning, out-of-home placement, and length of...
Viktor B. Nöhles, MA; Charlotte Jaite, PhD; Kerstin Rubarth, PhD; Fabiola H. Heuer, MSc; Katja Bödeker, PhD; Laura Golz, MSc; Sibylle M. Winter, MD; Christoph U. Correll, MD
JCP
Novel Quality Control Metric for the Pharmacotherapy of Major Depressive Disorder: Measuring Guideline Concordance and Its Impact on Symptom Severity
Original Research

January 3, 2024

This study created a new score to measure treatment guideline adherence and found that following guidelines resulted in lower MDD symptom severity.
Mason T. Breitzig, MPH; Fan He, PhD; Lan Kong, PhD; Guodong Liu, PhD; Daniel A. Waschbusch, PhD; Jeff D. Yanosky, ScD; Erika F. H. Saunders, MD; Duanping Liao, MD, PhD
JCP
Telehealth Collaborative Care Led by Clinical Pharmacists for People With Psychosis or Bipolar Disorder: A Propensity Weighted Comparison With Usual Psychiatric Care
Original Research

January 29, 2024

A telehealth collaborative care program with psychiatric clinical pharmacists had strong patient participation and was associated with greater medication adherence and guideline-concordant preventive care.
Esti Iturralde, PhD; Lisa Fazzolari, DO; Natalie E. Slama, MPH; Stacey E. Alexeeff, PhD; Stacy A. Sterling, MSW, DrPH; Sameer Awsare, MD; Maria T. Koshy, MD; Macy Shia, PharmD
JCP
The Clinician’s Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia
Original Research

January 24, 2024

Accurately identifying the severity and functional impact of tardive dyskinesia is essential. This report describes a new instrument, the Clinician’s Tardive Inventory, which aims to address shortcomings of existing...
Richard M. Trosch, MD; Cynthia L. Comella, MD; Stanley N. Caroff, MD; William G. Ondo, MD; Alicia C. Shillington, PhD, MPH; Brandon J. LaChappelle, MPH; Robert A. Hauser, MD; Christoph U. Correll, MD; Joseph H. Friedman, MD
JCP
Associations of MSK1 Methylation and Executive Function With Suicidal Ideation in Adolescents With Major Depressive Disorder: A Prospective Cohort Study
Original Research

February 21, 2024

Among 66 adolescents with MDD, those with suicidal ideation had worse executive function and higher MSK1 methylation than those without suicidal ideation.
Peiwei Xu, MD, PhD; Yuanmei Tao, MD; Hang Zhang, MD; Meijiang Jin, MD; Hanmei Xu, MD; Shoukang Zou, MD; Fang Deng, MD; Lijuan Huang, MD; Hong Zhang, MD; Xiaolan Wang, MD; Xiaowei Tang, MD; Yanping Wang, MD; Li Yin, MD, PhD; Xueli Sun, MD
JCP
Randomized Controlled Trial of a Brief Video Intervention to Reduce Self-Stigma of Mental Illness
Original Research

March 6, 2024

A 2-minute social contact–based video intervention decreased self-stigma in young people with ongoing mental health conditions.
Doron Amsalem, MD; Samantha E. Jankowski, MA; Philip Yanos, PhD; Lawrence H. Yang, PhD; John C. Markowitz, MD; R. Tyler Rogers, MA; T. Scott Stroup, MD; Lisa B. Dixon, MD, MPH; Leah G. Pope, PhD
JCP
Effect of Lurasidone on Social Functioning in Schizophrenia: Post Hoc Analysis of the JEWEL Study
Original Research

January 31, 2024

Impaired social functioning in schizophrenia affects personal recovery. This analysis looked at the effects of lurasidone on social functioning in schizophrenia during a double-blind, placebo-controlled study and subsequent open-label...
Itaru Miura, MD, PhD; Fumiya Sano, PhD; Reiko Sakaguchi, MSc; Keisuke Okamoto, MSc; Hidenori Maruyama, MSc
JCP
Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial
Original Research

February 28, 2024

In this post hoc analysis, treatment of acutely exacerbated schizophrenia with aripiprazole lauroxil or paliperidone palmitate was well tolerated, consistent with the safety profiles of these medications.
Leslie Citrome, MD, MPH; Sergey Yagoda, MD; Ilda Bidollari, MD, MBA; Meihua Wang, PhD
JCP
The Effectiveness of Metformin in Managing Second Generation Antipsychotic–Induced Weight Gain in Children and Adolescents
Original Research

December 20, 2023

Pediatric patients are vulnerable to antipsychotic-induced weight gain (AIWG). This study assessed the effectiveness of metformin on AIWG and explored whether timing of metformin initiation and premorbid obesity moderated...
Hua Chen, MD, PhD; Ning Lyu, MS; Chadi Calarge, MD; Austin De La Cruz, PharmD, BCPP; Wenyaw Chan, PhD
JCP
Effects of Prenatal Exposure to Second-Generation Antipsychotics on Development and Behavior Among Preschool-Aged Children: Preliminary Results From the National Pregnancy Registry for Psychiatric Medications
Original Research

March 13, 2024

Outcomes of children exposed in utero to second-generation antipsychotics (SGAs) were compared to those of children unexposed to SGAs in a cohort of mothers with a history of psychiatric...
Carol Swetlik, MD; Lee S. Cohen, MD; Lauren A. Kobylski, MPH; Ellen T. Sojka, BA; Parker C. Killenberg, BS; Marlene P. Freeman, MD; Adele C. Viguera, MD

Cross Talk: Case Conferences From MGH

JCP
“When Will All of This End?”: A 65-Year-Old Man With Amyotrophic Lateral Sclerosis and Psychiatric Distress
Cross Talk: Case Conferences From MGH

December 13, 2023

This case shows the psychological and pharmacologic aspects of providing tailored care for a patient with ALS. The authors discuss how these approaches impacted the patient and how ALS-specific...
Ethan G. Lester, PhD; Ottavio V. Vitolo, MD; Alice Flaherty, MD, PhD; Yvan Beaussant, MD, MSc; Margaret Cramer, PhD, ABPP; Rebecca Harley, PhD; Jonah N. Cohen, PhD

Commentary

JCP
The Intense Psychological Burden of ALS, the Enduring Strength of People Living With ALS, and the Tools We Can Use to Help
Commentary

December 13, 2023

Commenting on a recent article by Lester et al, the authors discuss the psychological impacts of diagnosis, genetic testing, and disease progression on patients with amyotrophic lateral sclerosis (ALS).
Doreen T. Ho, MD; James D. Berry, MD, MPH
JCP
Enriching the Assessment of Suicidal Ideation: Learning From Digital Studies
Commentary

January 17, 2024

The processes involved in the generation of suicidal ideation (SI) can be distinguished from those involved in the acts themselves. This commentary notes that the rise of digital health...
Philippe Courtet, MD, PhD; Enrique Baca-García, MD, PhD
JCP
What Does a Systematic Review of Cannabis and PTSD Tell Us? That We Need to Learn More
Commentary

February 14, 2024

Dr Ostacher discusses a review by Rodas et al and points to a need for clear answers on how best to advise patients with PTSD and other psychiatric illness...
Michael J. Ostacher, MD, MPH, MMSc

Clinical and Practical Psychopharmacology

JCP
Physical Exercise and Health, 6: Sedentary Time, Independent of Health-Related Physical Activity, as a Risk Factor for Dementia in Older Adults
Clinical and Practical Psychopharmacology

February 7, 2024

Dr Andrade reviews and discusses research on the relationship of sedentary behaviors to development of dementia.
Chittaranjan Andrade, MD
JCP
Physical Exercise and Health, 5: Sedentary Time, Independent of Health-Related Physical Activity, as a Risk Factor for Adverse Physical Health and Mental Health Outcomes
Clinical and Practical Psychopharmacology

January 29, 2024

Topics include why sedentariness is important, how it is defined and assessed, and why sedentary behaviors are common in daily life.
Chittaranjan Andrade, MD
JCP
Exposure of Pregnancy to Pregestational Diabetes, Gestational Diabetes, and Antidiabetic Medications With Especial Focus on Major Congenital and Cardiac Malformations in Offspring
Clinical and Practical Psychopharmacology

March 11, 2024

Diabetes is prevalent and poses risks to both mother and child during pregnancy. Evidence shows that diabetes is best treated during pregnancy, with insulin a first-line treatment and metformin...
Chittaranjan Andrade, MD

ASCP Corner

JCP
Where Does Lamotrigine Fit in the Pharmacotherapy of Mood Disorders? An Evidence-Based Appraisal
ASCP Corner

January 31, 2024

This article provides a practical overview of the evidence supporting lamotrigine’s efficacy and identifies shortcomings of previous study designs.
Joseph F. Goldberg, MD

Case Report

JCP
Suicidality Emerging From Rapid Venlafaxine Discontinuation: A Challenge–Dechallenge–Rechallenge Case Report
Case Report

January 22, 2024

This case report presents a patient with no history of suicidal crisis who experienced 2 suicidal crises within 6 months, each directly following rapid discontinuation of venlafaxine.
Milutin Kostic, MD, PhD; Martin Plöderl, PhD; Michael Hengartner, PhD; Jelena Buzejic, MD

Letter to the Editor

JCP
Testing for Sleep-Disordered Breathing in Psychiatric Practice: Don’t Sleep on It!
Letter to the Editor

January 10, 2024

Dr Barry Krakow comments on Benca and colleagues’ recent review of sleep apnea in psychiatric practice and calls for clinicians to screen for sleep-disordered breathing at intake.
Barry Krakow, MD
JCP
Relative Risk of Breast Cancer Associated With Prolactin-Increasing Antipsychotic Use
Letter to the Editor

January 22, 2024

The authors provide additional relative risk data in response to Dr Andrade’s comments on their study.
Heidi Taipale, PhD; Marco Solmi, MD, PhD; Christoph U. Correll, MD, Professor; Jari Tiihonen, MD, PhD, Professor
JCP
Reckoning Risk Retrospectively: Reply to Taipale et al
Letter to the Editor

January 22, 2024

In a reply to Taipale and colleagues, Dr Andrade discusses estimation of risk in case-control studies and in RCTs.
Chittaranjan Andrade, MD

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe